Latest news with #ConcentraBiosciences
Globe and Mail
3 days ago
- Business
- Globe and Mail
Shareholder Alert: The Ademi Firm Investigates Whether CARGO Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences . Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO's product candidates that occurs within two years following closing. CARGO insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for CARGO by imposing a significant penalty if CARGO accepts a competing bid. We are investigating the conduct of the CARGO board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Yahoo
29-07-2025
- Business
- Yahoo
Jefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold Rating
CARGO Therapeutics, Inc. (NASDAQ:CRGX) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 8, Jefferies raised its price target for CARGO Therapeutics, Inc. (NASDAQ:CRGX) from $3.70 to $5.00 while keeping a 'Hold' rating. This decision came after the company announced that it has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC. A surgeon wearing a medical mask, examining a cancer patient in a surgical facility. Concentra Biosciences, LLC will acquire CARGO Therapeutics, Inc. (NASDAQ:CRGX) for $4.379 in cash per share. The transaction is expected to close in August 2025. Jefferies projects that the total value for shareholders could reach up to $5 per share at closing, based on projected cash burn and potential asset sale proceeds. CARGO Therapeutics, Inc. (NASDAQ:CRGX) is a biotechnology company focused on the development of CAR T-cell therapies for cancer patients. While we acknowledge the potential of CRGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
23-07-2025
- Business
- Associated Press
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, TASK, OLO on Behalf of Shareholders
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc. (NASDAQ: ITOS)'s sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. If you are an iTeos shareholder, click here to learn more about your rights and options. ZimVie Inc. (NASDAQ: ZIMV)'s sale to an affiliate of ARCHIMED for $19.00 in cash per share. If you are a ZimVie shareholder, click here to learn more about your rights and options. TaskUs, Inc. (NASDAQ: TASK)'s sale to affiliates of Blackstone and executives and founders of TaskUs for $16.50 per share. If you are a TaskUs shareholder, click here to learn more about your rights and options. Olo Inc. (NYSE: OLO)'s sale to Thoma Bravo for $10.25 per share in cash. If you are an Olo shareholder, click here to learn more about your legal rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. One World Trade Center 85th Floor New York, NY 10007 (212) 763-0060 [email protected] [email protected]
Globe and Mail
21-07-2025
- Business
- Globe and Mail
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos shareholders. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. Halper Sadeh encourages iTeos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether iTeos and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for iTeos shareholders; (2) determine whether Concentra is underpaying for iTeos; and (3) disclose all material information necessary for iTeos shareholders to adequately assess and value the merger consideration. On behalf of iTeos shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
